• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在复发缓解型多发性硬化症患者中使用芬戈莫德治疗期间的心脏复极。

Cardiac repolarization during fingolimod treatment in patients with relapsing-remitting multiple sclerosis.

机构信息

Department of Clinical Physiology and Nuclear Medicine Kuopio University Hospital University of Eastern Finland Kuopio Finland.

Neuro CenterDepartment of Neurology Kuopio University Hospital University of Eastern Finland Kuopio Finland.

出版信息

Brain Behav. 2018 Jan 30;8(2):e00925. doi: 10.1002/brb3.925. eCollection 2018 Feb.

DOI:10.1002/brb3.925
PMID:29484274
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5822581/
Abstract

BACKGROUND

Fingolimod is a sphingosine-1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis (RRMS). Despite an established effect on heart rate, the effect of fingolimod on cardiac repolarization is not completely known.

METHODS

Twenty-seven patients with RRMS underwent 24-hr ambulatory ECG before fingolimod (baseline), at the day of fingolimod initiation (1D) and after three-month treatment (3M). The mean values of RR-interval as well as QT-interval corrected by Bazzet's (QTcBaz) and Fridericia's (QTcFri) formula were compared between baseline, 1D, and 3M over 24-hr period as well as at daytime and nighttime.

RESULTS

QTcBaz over 24-hr was shorter at 1D (414 ± 20 ms,  < .001) and at 3M (414 ± 20 ms,  < .001) than at baseline (418 ± 20 ms). In contrast, QTcFri over 24-hr was longer at 1D (410 ± 19 ms,  < .001) but similar at 3M (406 ± 19 ms,  = .355) compared to baseline (407 ± 19 ms). Daytime QTcBaz was shorter at 1D ( < .001) and at 3M ( = .007), whereas daytime QTcFri was longer at 1D ( < .05) but similar at 3M ( = ns) compared to baseline. During the night, changes were observed neither in QTcBaz nor in QTcFri between baseline, 1D, and 3M.

CONCLUSIONS

Changes in cardiac repolarization after fingolimod initiation were mild and occurred at daytime. Ambiguously, QTcBaz demonstrated shortening, whereas QTcFri showed prolongation in cardiac repolarization after fingolimod initiation. The formula applied for QT-interval correction needs to be taken carefully into account as evaluating pharmacovigilance issues related to fingolimod.

摘要

背景

芬戈莫德是一种鞘氨醇-1-磷酸受体调节剂,用于治疗复发缓解型多发性硬化症(RRMS)。尽管其对心率有明确的影响,但芬戈莫德对心脏复极的影响尚不完全清楚。

方法

27 例 RRMS 患者在接受芬戈莫德治疗前(基线)、起始日(1D)和治疗 3 个月(3M)时进行 24 小时动态心电图监测。比较 24 小时内、白天和夜间 RR 间期和校正后的 QT 间期(QTcBaz 和 QTcFri 公式)的平均值在基线、1D 和 3M 之间的差异。

结果

24 小时 QTcBaz 在 1D(414±20ms, <.001)和 3M(414±20ms, <.001)时短于基线(418±20ms)。相比之下,24 小时 QTcFri 在 1D 时较长(410±19ms, <.001),但在 3M 时与基线相似(406±19ms, =.355)。1D 和 3M 时白天 QTcBaz 短于基线( <.001),而白天 QTcFri 长于基线( <.05)但在 3M 时与基线相似( =ns)。夜间,基线、1D 和 3M 之间 QTcBaz 和 QTcFri 均无变化。

结论

芬戈莫德起始后心脏复极的变化轻微,发生在白天。QTcBaz 表现为缩短,而 QTcFri 表现为延长,提示 QTcBaz 与 QTcFri 可能用于评价与芬戈莫德相关的药物警戒问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62d9/5822581/a781fc1984e4/BRB3-8-e00925-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62d9/5822581/6c1c45e19bbe/BRB3-8-e00925-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62d9/5822581/a781fc1984e4/BRB3-8-e00925-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62d9/5822581/6c1c45e19bbe/BRB3-8-e00925-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62d9/5822581/a781fc1984e4/BRB3-8-e00925-g002.jpg

相似文献

1
Cardiac repolarization during fingolimod treatment in patients with relapsing-remitting multiple sclerosis.在复发缓解型多发性硬化症患者中使用芬戈莫德治疗期间的心脏复极。
Brain Behav. 2018 Jan 30;8(2):e00925. doi: 10.1002/brb3.925. eCollection 2018 Feb.
2
Modulation of sphingosine receptors influences circadian pattern of cardiac autonomic regulation.鞘氨醇受体的调节影响心脏自主神经调节的昼夜节律模式。
Physiol Rep. 2016 Sep;4(17). doi: 10.14814/phy2.12870.
3
Effects of Three Months Fingolimod Therapy on Heart Rate.三个月芬戈莫德治疗对心率的影响。
J Neuroimmune Pharmacol. 2015 Dec;10(4):651-4. doi: 10.1007/s11481-015-9619-8. Epub 2015 Jun 20.
4
The impact of multiple sclerosis onset symptom on cardiac repolarization.多发性硬化症发病症状对心脏复极的影响。
Brain Behav. 2017 Jun 5;7(7):e00742. doi: 10.1002/brb3.742. eCollection 2017 Jul.
5
Fingolimod (Gilenya ) in multiple sclerosis: bradycardia, atrioventricular blocks, and mild effect on the QTc interval. Something to do with the L-type calcium channel?芬戈莫德(捷灵亚)治疗多发性硬化症:心动过缓、房室传导阻滞以及对QTc间期的轻微影响。与L型钙通道有关?
Fundam Clin Pharmacol. 2017 Aug;31(4):392-402. doi: 10.1111/fcp.12284. Epub 2017 Apr 26.
6
Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis.芬戈莫德对多发性硬化症患者心脏自主神经调节的影响。
Mult Scler. 2016 Jul;22(8):1080-5. doi: 10.1177/1352458515604384. Epub 2015 Sep 11.
7
Index of cardiac-electrophysiological balance in relapsing-remitting multiple sclerosis patients treated with fingolimod.复发缓解型多发性硬化症患者接受芬戈莫德治疗后的心脏电生理平衡指数。
Mult Scler Relat Disord. 2023 Aug;76:104827. doi: 10.1016/j.msard.2023.104827. Epub 2023 Jun 10.
8
Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing.中枢自主神经功能障碍延缓芬戈莫德所致心率减慢的恢复。
PLoS One. 2015 Jul 6;10(7):e0132139. doi: 10.1371/journal.pone.0132139. eCollection 2015.
9
Sequence of cardiovascular autonomic alterations after fingolimod initiation.芬戈莫德起始治疗后心血管自主神经改变的顺序。
Ann Noninvasive Electrocardiol. 2017 Sep;22(5). doi: 10.1111/anec.12443. Epub 2017 Feb 13.
10
Tp-Te interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis.
Int J Cardiol. 2016 Oct 15;221:881-5. doi: 10.1016/j.ijcard.2016.07.134. Epub 2016 Jul 9.

本文引用的文献

1
Cardiac action potential repolarization revisited: early repolarization shows all-or-none behaviour.心脏动作电位复极化再探:早期复极表现出全或无行为。
J Physiol. 2017 Nov 1;595(21):6599-6612. doi: 10.1113/JP273651. Epub 2017 Oct 9.
2
Risk factors for QTc-prolongation: systematic review of the evidence.致 QT 间期延长的风险因素:证据的系统综述。
Int J Clin Pharm. 2017 Feb;39(1):16-25. doi: 10.1007/s11096-016-0414-2. Epub 2016 Dec 23.
3
Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis.
芬戈莫德对多发性硬化症患者心脏自主神经调节的影响。
Mult Scler. 2016 Jul;22(8):1080-5. doi: 10.1177/1352458515604384. Epub 2015 Sep 11.
4
Effects of Three Months Fingolimod Therapy on Heart Rate.三个月芬戈莫德治疗对心率的影响。
J Neuroimmune Pharmacol. 2015 Dec;10(4):651-4. doi: 10.1007/s11481-015-9619-8. Epub 2015 Jun 20.
5
The effect of the sphingosine-1-phosphate analogue FTY720 on atrioventricular nodal tissue.鞘氨醇-1-磷酸类似物FTY720对房室结组织的作用。
J Cell Mol Med. 2015 Jul;19(7):1729-34. doi: 10.1111/jcmm.12549. Epub 2015 Apr 13.
6
Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications.芬戈莫德对心脏和血管的影响:作用机制和临床意义。
Am Heart J. 2014 Nov;168(5):632-44. doi: 10.1016/j.ahj.2014.06.028. Epub 2014 Jul 11.
7
The autonomic balance predicts cardiac responses after the first dose of fingolimod.自主神经平衡可预测首次服用芬戈莫德后的心脏反应。
Mult Scler. 2015 Feb;21(2):206-16. doi: 10.1177/1352458514538885. Epub 2014 Jun 23.
8
Heart-brain interactions in cardiac arrhythmia.心脏心律失常中心-脑相互作用。
Heart. 2011 May;97(9):698-708. doi: 10.1136/hrt.2010.209304. Epub 2011 Mar 1.
9
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.口服芬戈莫德或肌肉注射干扰素治疗复发型多发性硬化。
N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.
10
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.一项口服芬戈莫德治疗复发性多发性硬化的安慰剂对照试验。
N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.